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 Abstract 
More than 180 millions of subjects in the world are infected by Hepatitis C Virus (HCV), 
and about 20% of them with HCV chronic infection progress to cirrhosis. Furthermore, 
numerous HCV extrahepatic manifestations have been reported in up to 74% of patients, as 
mixed cryoglobulinemia, lymphomas, rheumatic disorders, autoimmune thyroiditis, 
hypothyroidism, papillary thyroid cancer, and type 2 diabetes. Advances in understanding the 
HCV life cycle, and the inflammatory processes (involving a complex network of cytokines 
and chemokines) associated with HCV chronic infection, have led to substantial 
advancements in therapy. The combination of ribavirin and PEGylated interferon-α was 
the standard of therapy for HCV chronically infected patients in the last decades. 
However, interferon has limited effectiveness and is associated with severe adverse effects. 
Recently, direct-acting antivirals (DAAs) that act as inhibitors of N5SA, or polymerase, 
or protease have been shown to result in shorter duration of therapy, better efficacy 
and tolerance, with respect to ribavirin and PEGylated interferon-α . Circulating CXCL10 
levels, and the interleukin(IL)-28B gene polymorphisms, are associated with the success 
of the therapy both with DAAs or ribavirin and PEGylated interferon-alpha. New DAAs 
targeting the HCV at various molecular levels have been developed to eradicate HCV. 
Moving to interferon-free therapies should offer new treatments for resistant HCV genotypes, 
and for ineligible patients or patients failing to respond to prior therapies. 
Many efforts have been made to understand the factors that are involved with 
clearance of HCV to personalize the therapy for each patient, with the aim to reduce 
side effects, increasing the sustained virologic response rate, and to prevent the 
progression of the disease. 
 
 
EDITORIAL 
 
More than 180 millions of subjects in the world are infected by Hepatitis C Virus (HCV), 
and about 20% of them with HCV chronic infection progress to cirrhosis [1]. 
Furthermore, numerous extrahepatic manifestations (HCV-EHMs) have been reported in up 
to 74% of patients [2-5]. HCV strategies that limit or delay the initiation of innate antiviral 
responses are important in determining the final outcome of the infection [6]. High rate of 
replication and error prone genome replication machinery enable HCV to evade immune 
recognition. This delay of an effective immune response allows HCV to establish widespread 
infection in liver and extra-hepatic tissues and cells. Changing viral epitopes induces a failure 
of the adaptive immune response. Moreover, neutralizing antibody epitopes may be hidden by 
decoy structures, lipoproteins and glycans [7, 8]. Also, T cell responses fail due to changing 
viral epitope sequences; while the phenomenon of exhaustion is probably evolved to limit 
immune-mediated pathology [9]. As a result, immune-mediated clearance of HCV infection is 
occurring only in about 20% of people, by innate and adaptive immune mechanisms [10].  
A complex orchestration of cytokines and chemokines coordinate immune response, 
both innate and adaptive, in the initial phases of HCV infection, and plays a pivotal role in 
controlling viral replication and liver damage [11]. Among cytokines, it is well known that the 
production of and/or response to interferons (IFNs) are very important in the induction of the 
immune response during chronic HCV infection (CHC) [12, 13], and several studies have 
shown that patients with CHC have a deregulated IFNs response [14]. In fact, patients who 
already have a high level of endogenous IFN-stimulated genes (ISGs) expression do not 
achieve viral clearance or have a poor response to treatment with IFN-α [15]. The viral and/or 
host factors that are responsible for the greater baseline ISGs expression in certain HCV 
patients remain to be determined [16]. Recently, it has been shown that type III IFNs, and in 
particular the new discovered IFN-λ4, play a dominant role in driving ISGs response and in 
contributing to the viral clearance or persistence [17-19].  
A predominance of the Th1 immune response (and related cytokines/chemokines) has been 
shown in CHC and in HCV-EHMs [20, 21]. Interferons, and chemokines inducible by 
interferon-γ [(C-X-C motif) ligand (CXCL)9, -10 and -11] recruit inflammatory cells into 
the hepatic parenchyma (when the infection is not controlled) producing chronic 
inflammation and fibrosis of the liver, that may results in hepatic cirrhosis [22-25]. A 
complex dysregulation of cytokines and chemokines response is associated with HCV 
systemic manifestations [mixed cryoglobulinemia (MC), lymphomas, autoimmune 
diseases of the thyroid (AITD), type 2 diabetes], and involves overall the Th1 
cyokines/chemokines [23, 26]. HCV escapes immunity interfering at various levels with 
cytokines/chemokines, and inducing a Th2/Tc2 immune response [26, 27]. The 
administration of interferon-α can induce the HCV clearance during CHC, and can 
revert the progression to cirrhosis, reducing CXCL10 levels [25, 28]. It has been 
suggested that agents directed to neutralize CXCL10 could increase the 
responsiveness of patients to traditional therapies of HCV infection, simultaneously 
reducing inflammatory immune cell activation [29]. Many studies have shown that both 
circulating CXCL10, and polymorphisms of interleukin (IL)-28B, could be used as 
prognostic markers of efficacy of HCV therapies [30-33]. Other studies have also shown 
that HCV clearance by direct-acting antiviral (DAAs) therapies decreases circulating CXCL10 
levels [34].  
HCV infection regulates a number of microRNAs (miRNAs), which are able to exert an effect 
on liver biology and pathology [35, 36]. In HCV infected hepatocytes miRNAs can directly 
regulate HCV replication through interaction with the HCV genome [37]. Moreover miRNAs 
induced by HCV can indirectly control critical virus-associated host pathways, inducing liver 
fibrosis, cirrhosis, and/or hepatocellular carcinoma [38, 39]. Recently, circulating miRNAs are 
emerging as biomarkers for HCV associated disorders. Considerable efforts have been 
employed to investigate the change in the circulating miRNA pattern in HCV infection and 
related diseases [40, 41]. Distinctive circulating miRNA patterns are associated with 
HCV infection and HCV-related hepatic diseases [42], suggesting that miRNAs are non-
invasive biomarkers to evaluate the diagnosis and prognosis of these disorders [43]. 
Treatment for HCV infection has recently progressed from poorly tolerated IFN-α therapy and 
with very low cure rates, to highly effective oral DAAs with cure rates above 90% for almost all 
patients, and with little adverse effects [44-46]. Understanding of the viral lifecycle, with 
recognition of targets that could be inhibited by small molecules, has permitted the 
production of DAAs, that inhibit protease, non-structural 5a (NS5A), and nucleotide 
and non-nucleotide polymerase [47-49]. Initially DAAs have been used with Pegylated-
Interferon-α  (Peg- IFN) and Ribavirin (RBV), and subsequently in combination without the 
need for IFNs [50]. Rational DAAs combinations have overcome the major challenge of rapid 
emergence of drug resistance [51]. Second-generation DAAs agents in each class have 
further improved safety and efficacy profiles, reducing drug-drug interactions and adverse 
side effects [52-54].  
In the new era of DAAs therapy in which elimination of HCV infection is a real possibility, HCV 
infected cell culture models are important for the identification of therapeutic targets, testing 
candidate drugs, and profiling of therapeutic strategies [55-58]. The development of protocols 
to grow HCV in culture and generate hepatocyte cell lines from specific individuals holds great 
promise to investigate the mechanisms exploited by the virus to spread the infection and the 
host factors critical for HCV replication and propagation, or resistance to infection [59-63]. 
These models could be used for the development of drugs targeting host factors essential for 
virus replication, holding great promises in further increasing treatment efficacy [64].  
The most common HCV-EHMs of HCV infection is MC syndrome (MCs), an immune-complex 
mediated vasculitis, involving joints, skin, peripheral nerves, and internal 
organs. In the majority of individuals, MCs shows a mild, slow-progressive clinical course 
needing only symptomatic treatments [65-68]. However the etiologic therapy was considered 
the first-line option in MCs patients and, in the past two decades, antiviral treatment with RBV 
plus Peg-IFN represented the standard of care [69]. Rapidly progressive, diffuse MC 
vasculitis with multiple organ involvement may be successfully treated with aggressive 
immunosuppressive and anti-inflammatory therapies, mainly based on cyclophosphamide or 
rituximab, high dose corticosteroids, and plasmapheresis [70]. The recent introduction of 
DAAs substantially changed the treatment of HCV infection. DAAs anti-HCV therapy seem to 
be safe and effective in patients with MC and MCs from the virological and clinical points of 
view, thus confirming the key role played by HCV eradication in inducing MC remission [71- 
73]. The combination, or a sequence, of antiviral and 
immunosuppressive treatments has been shown to  be  useful in the therapy of MCs 
patients with major clinical manifestations. In the clinical practice, treatment of MCs 
needs to be personalized for each patient in relation to clinical symptoms and the 
severity of the diseases [74-76]. 
On the bases of epidemiological data, biological investigation, as well as clinical observations, 
HCV is increasingly recognized to be involved in the pathogenesis of a variety of histological 
types of B-cell non-Hodgkin' s lymphoma (B-NHL) [77-80]. To understand the 
mechanisms related to HCV persistence, and lymphomagenesis, is necessary to 
develop new therapies with the aim to prevent and to treat B-NHLs [81, 82]. It has been 
also observed that at least some types of HCV-related indolent B-NHLs disappear after 
successful antiviral treatment, strongly reinforcing the hypothesis of a HCV-induced 
lymphomagenesis [83]. The role of DAAs in the prevention and treatment of HCV associated 
lymphoproliferation remains to be clarified [84, 85].  
Other HCV-EHMs are various rheumatic disorders (mainly arthritis, sicca syndrome, 
osteosclerosis, etc) [86-91]. The management of HCV-associated rheumatic diseases is 
particularly difficult because of the coexistence of complex immunological disorders and 
HCV infection, and needs to be personalized in each patient [92-94]. 
The occurrence of autoimmune thyroiditis, hypothyroidism, papillary thyroid cancer and type 2 
diabetes is also more frequent in CHC: these disorders can significantly impact the quality of 
life of HCV patients, the course of the disease, and the effect of therapies [95-98]. The role of 
DAAs in the prevention and treatment of these endocrine disorders remains to be clarified.  
In this issue, we focus on the recent advancements in the viral and host factors influencing 
their interplay, highlighting current knowledge in the inflammatory processes (and the inherent 
network of cytokines and chemokines) associated with CHC, and illustrate the multifaceted 
HCV-EHMs, that heavily affect the quality of life of HCV patients. We then describe how the 
development of reliable systems to propagate the virus in vitro and the identification of small 
molecules targeting key steps of HCV replication have led to substantial advancements in the 
therapy. Finally, we give an overview of current approaches for treatment and of novel DAAs 
targeting various stages of the life of HCV and holding promise to eradicate HCV 
infection. Moving to IFN-free therapies should offer new treatments for resistant HCV 
genotypes, and for ineligible patients or patients failing to respond to prior therapies. The 
knowledge of viral and host factors associated with the clearance of HCV is very 
important to personalize the therapy in each patient, increasing the sustained virologic 
response rates, preventing the progression of hepatic disease, and reducing adverse 
side effects. 
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